Business, energy, technology, markets and global industry news from Business News Today
Features & Analysis

Gene editing can nearly eliminate sickle cell crises. A daily pill may still reach far more patients

Novo Nordisk’s submission of etavopivat for regulatory approval in the United States and Europe could look, at first glance, like another incremental development in a sickle cell disease market already transformed by gene therapy. The once-daily oral pyruvate kinase activator reduced annualised vaso-occlusive crises by 27% in the pivotal Phase 3 HIBISCUS study, while 48.7% of treated participants achieved a haemoglobin increase greater than 1 g/dL at Week 24 compared with 7.2% receiving placebo.

Those numbers are far less dramatic than the crisis-free outcomes reported with successful autologous gene therapies. Yet that comparison misses what may become the defining commercial and public-health question in sickle cell disease.

The future market is unlikely to be decided simply by which therapy produces the largest effect in a clinical trial. It is increasingly separating into two treatment models with radically different economics, infrastructure requirements and patient journeys. One involves potentially transformative one-time genetic procedures delivered through specialist transplant centres. The other involves conventional medicines that may produce smaller individual treatment effects but can be prescribed repeatedly, manufactured at pharmaceutical scale and potentially used across a much larger population.

Etavopivat sits squarely in the second model. If regulators accept the HIBISCUS package, Novo Nordisk could enter a sickle cell market in which genetic therapies are proving clinically powerful but remain operationally difficult to scale, while another oral pyruvate kinase activator, mitapivat, is already approaching a separate FDA decision.

The result may not be a winner-takes-all contest between pills and gene editing. Sickle cell disease increasingly looks like a market in which the most sophisticated therapy and the most scalable therapy can both be valuable for completely different reasons.

Why does etavopivat matter when sickle cell disease already has one-time genetic treatments?

Casgevy and Lyfgenia fundamentally changed expectations for sickle cell treatment when the FDA approved both products in December 2023. Casgevy became particularly significant because it was the first approved treatment using CRISPR-based genome editing, while subsequent label expansion in July 2026 made the therapy available in the United States to children as young as two years with recurrent vaso-occlusive crises.

These therapies can produce profound reductions in vaso-occlusive events following successful treatment. They also require one of the most complex treatment journeys in modern medicine.

Patients undergo stem-cell mobilisation and collection before their cells are genetically modified outside the body. They subsequently receive myeloablative conditioning to make room in the bone marrow for the modified cells, followed by infusion, engraftment, specialist monitoring and prolonged follow-up.

That creates a treatment proposition entirely different from taking a tablet at home.

Casgevy carries a U.S. list price of about $2.2 million, while Lyfgenia was launched at approximately $3.1 million. Those figures exclude some of the surrounding costs associated with collection, conditioning, hospitalisation and supportive care, although payers and manufacturers may negotiate arrangements that differ materially from headline prices.

The logistical burden matters just as much as acquisition cost. A patient needs access to an authorised treatment centre, must be medically suitable for intensive conditioning and has to accept the immediate and long-term implications of an autologous stem-cell procedure.

Etavopivat does not offer the same treatment proposition. It is being developed as a once-daily medicine for adolescents and adults aged 12 years and older that could be incorporated into conventional chronic sickle cell management.

The relevant question is therefore not whether a 27% reduction in vaso-occlusive crises looks smaller than the results produced by successful gene therapy. It is how many patients can realistically reach each treatment.

What did HIBISCUS establish about etavopivat’s ability to modify sickle cell disease?

HIBISCUS enrolled approximately 440 adolescents and adults with sickle cell disease who had experienced between two and 15 vaso-occlusive crises during the previous year. Participants could continue receiving standard-of-care therapy, allowing the study to test whether etavopivat provided additional benefit rather than replacing established management.

Novo Nordisk reported that the trial met both co-primary endpoints.

Etavopivat reduced annualised vaso-occlusive crises by 27% compared with placebo over 52 weeks. The median time to first vaso-occlusive crisis was also extended from approximately 20.9 weeks with placebo to 38.4 weeks with etavopivat, representing a delay of around four months.

The haemoglobin endpoint provided a separate signal of red-blood-cell improvement. At Week 24, 48.7% of patients receiving etavopivat had experienced a haemoglobin increase greater than 1 g/dL compared with 7.2% receiving placebo, an adjusted difference of 41.2 percentage points.

Novo Nordisk has additionally reported a significant reduction in transfusion risk.

The important limitation is that the complete Phase 3 dataset has not yet been publicly presented or peer reviewed. The regulatory applications have therefore advanced ahead of the detailed scientific presentation available to clinicians and outside researchers.

That makes the topline result sufficient to understand why Novo Nordisk filed the medicine, but insufficient for a definitive assessment of the complete benefit-risk profile. Detailed adverse-event frequencies, subgroup outcomes, discontinuations and other secondary measures will matter once the full HIBISCUS analysis becomes available.

How does changing red-blood-cell metabolism reduce sickling without editing the sickle mutation?

Etavopivat does not correct the genetic mutation responsible for sickle haemoglobin. Instead, it attempts to change the metabolic environment inside the red blood cell.

The medicine selectively activates the red-blood-cell isoform of pyruvate kinase, an enzyme involved in glycolysis. Sickle red blood cells typically have relatively low levels of adenosine triphosphate, or ATP, and elevated concentrations of 2,3-diphosphoglycerate.

Increasing pyruvate kinase activity is intended to raise ATP production while reducing 2,3-diphosphoglycerate. More ATP may help preserve red-cell membrane integrity and deformability, while lower 2,3-diphosphoglycerate increases haemoglobin’s affinity for oxygen.

That increase in oxygen affinity can delay the deoxygenated conditions under which sickle haemoglobin polymerises and red blood cells distort into the characteristic sickled shape.

Early clinical research with etavopivat supported the mechanism. In a small Phase 1 programme, investigators observed sustained increases in ATP, decreases in 2,3-diphosphoglycerate and increases in haemoglobin over 12 weeks of treatment.

HIBISCUS is important because it moves the concept beyond biochemical changes. A treatment for sickle cell disease ultimately needs to affect the painful vaso-occlusive events and chronic anaemia that drive patient morbidity, not simply improve laboratory measurements.

Why is the Oxbryta withdrawal an important warning for the next generation of sickle cell pills?

The sickle cell sector has already learned that improving haemoglobin biology does not guarantee durable clinical success.

Pfizer voluntarily withdrew Oxbryta, or voxelotor, globally in 2024 after emerging data raised concerns that its benefit no longer outweighed its risks. The FDA advised clinicians to stop prescribing the medicine after post-marketing studies showed a higher rate of vaso-occlusive crises among patients receiving Oxbryta compared with placebo.

That episode changed the evidentiary environment for oral sickle cell development.

A drug capable of increasing haemoglobin may look biologically attractive, but regulators and clinicians increasingly want evidence that the change translates into outcomes patients actually experience, particularly fewer crises, fewer hospitalisations or another clearly meaningful disease benefit.

HIBISCUS was designed around that challenge. Etavopivat did not rely solely on its haemoglobin response endpoint. The study also demonstrated a statistically significant reduction in annualised vaso-occlusive crises.

The full safety dataset will nevertheless deserve close scrutiny because red-cell metabolic manipulation involves a biological balance. Increasing haemoglobin without improving the overall behaviour and survival of sickle erythrocytes would be less meaningful than simultaneously reducing haemolysis and vaso-occlusion.

Novo Nordisk’s regulatory review will therefore test not simply whether etavopivat raises haemoglobin, but whether the combined efficacy and safety package demonstrates a favourable disease-modifying profile.

Why could mitapivat make the oral PK activator market more complicated?

Etavopivat may not have the pyruvate kinase field to itself.

Agios Pharmaceuticals is seeking an expanded indication for mitapivat in adult sickle cell disease. The FDA has extended the review deadline to February 1, 2027 after requesting additional information to assess whether a Risk Evaluation and Mitigation Strategy may be necessary.

The Phase 3 RISE UP trial produced a strong haemoglobin result. Approximately 41% of patients receiving mitapivat achieved the prespecified haemoglobin response compared with 3% receiving placebo.

The vaso-occlusive endpoint was less convincing. Annualised sickle cell pain crises occurred at a rate of 2.6 with mitapivat compared with 3.1 with placebo, but the difference did not reach statistical significance.

That difference between the two programmes could become strategically important.

Both medicines target pyruvate kinase biology, yet etavopivat has reported success on both haemoglobin and vaso-occlusive crisis endpoints, whereas mitapivat’s Phase 3 study clearly established haemoglobin improvement but did not demonstrate a statistically significant reduction in pain crises.

Direct comparisons would be inappropriate because HIBISCUS and RISE UP used different protocols, populations and statistical frameworks. However, regulators, clinicians and payers will ultimately evaluate how each medicine changes outcomes beyond the laboratory.

The competition may therefore become one of clinical profile rather than mechanism alone.

Could a daily pill have a larger addressable population than a potentially curative gene therapy?

This is where the commercial logic becomes most interesting.

Around 100,000 people in the United States live with sickle cell disease, while Novo Nordisk estimates approximately eight million people are affected globally. Most live in regions where advanced stem-cell transplantation infrastructure is limited or inaccessible.

Current autologous gene therapies cannot realistically be delivered to anything approaching that global population with today’s infrastructure.

Even in the United States, commercial uptake is developing gradually despite extraordinary clinical efficacy. Vertex Pharmaceuticals reported $99.2 million of Casgevy revenue during the third quarter of 2026, up 30% sequentially and nearly six-fold from the same quarter a year earlier.

That is genuine commercial acceleration. It also illustrates how differently gene therapy scales from a conventional medicine.

Every Casgevy patient represents an individual manufacturing and treatment journey. Commercial expansion requires qualified treatment centres, successful cell collection, manufacturing slots, conditioning capacity, payer authorisation and patients medically and practically able to complete the process.

An oral medicine can theoretically move through an established pharmaceutical supply chain and be prescribed by haematologists without requiring cell manufacturing or transplantation.

The clinical value per treated patient may be lower than successful gene therapy. The potential number of reachable patients could be dramatically higher.

Why does this create two different economic models for sickle cell drug developers?

Gene therapy economics are concentrated.

A manufacturer may receive millions of dollars for one successful treatment, although the therapy also carries high manufacturing, logistics and treatment-support costs. Revenue depends heavily on the number of patients who actually progress through the treatment pathway.

Oral therapy economics are distributed across years.

A chronic medicine is typically sold repeatedly for as long as patients continue treatment. Commercial value depends on price, treatment persistence, adherence, reimbursement and the number of eligible patients who initiate therapy.

This makes etavopivat strategically interesting for Novo Nordisk even if it never approaches the per-patient transformative potential of genetic treatment.

Novo Nordisk paid approximately $1.1 billion to acquire Forma Therapeutics in 2022, primarily gaining etavopivat and a broader foothold in haemoglobin disorders. The regulatory submissions now provide the first opportunity to determine whether that acquisition can produce a marketed rare-disease franchise.

The company also brings capabilities that a smaller biotechnology developer would have struggled to reproduce, including global manufacturing, payer relationships and commercial infrastructure across developed and emerging healthcare markets.

That matters because sickle cell disease is unusually global for a rare-disease pharmaceutical opportunity.

Will patients eventually choose between a pill and gene editing?

For some patients, potentially. For many others, the choice will be determined by clinical eligibility and access before personal preference becomes decisive.

A patient with severe recurrent vaso-occlusive crises who is medically suitable for gene therapy and has access to a specialist centre may consider a one-time genetic treatment attractive despite conditioning toxicity and procedural burden.

Another patient may not be able to undergo myeloablation, may lack access to a treatment centre or may simply be unwilling to accept the risks and disruption associated with transplantation.

Those patients still need better disease-modifying treatment.

Age creates another distinction. Casgevy’s U.S. indication now extends to children from two years of age, whereas Novo Nordisk is seeking etavopivat approval beginning at age 12. Gene therapy therefore has an unexpectedly broad age label despite its greater treatment complexity.

Long-term treatment goals may also differ. Genetic therapies aim to produce persistent biological change after one intervention. Etavopivat would need to be taken continuously to maintain its metabolic effect.

Discontinuation, adherence and chronic safety therefore matter much more for an oral therapy.

Could oral treatment be more important outside wealthy healthcare systems?

This may ultimately be the decisive global question.

The majority of people living with sickle cell disease are not located in the United States or Western Europe. Large patient populations exist across sub-Saharan Africa, India and other regions where specialist transplant capacity, genomic manufacturing infrastructure and healthcare financing are substantially more constrained.

Today’s autologous gene-therapy model is poorly matched to those conditions.

That does not mean a branded oral medicine automatically solves the access problem. Pricing, diagnosis, specialist care, drug distribution and long-term reimbursement remain major barriers. A treatment can be easy to manufacture relative to gene therapy and still remain unaffordable for many health systems.

Nevertheless, tablets create a fundamentally more scalable infrastructure proposition.

If etavopivat is eventually approved across multiple markets and its manufacturing cost permits wider pricing strategies over time, the medicine could reach health systems for which autologous gene therapy remains impractical.

That difference may become more important as sickle cell drug development increasingly considers global rather than purely U.S. commercial opportunity.

Does rising Casgevy revenue mean oral medicines will eventually become unnecessary?

The opposite is more likely.

Casgevy’s growing revenue demonstrates that patients and health systems can navigate a complex gene-editing treatment pathway when the clinical benefit is strong enough. Continued expansion into younger patients should increase the number of people for whom the therapy is an option.

Gene therapy adoption could therefore keep growing substantially without eliminating the oral market.

The analogy is not one treatment replacing another, but clinical segmentation becoming more sophisticated. Some patients may pursue a potentially long-lasting genetic intervention. Others may receive oral disease-modifying therapy for years. Some may move from chronic treatment to gene therapy later, assuming clinical eligibility and access.

Treatment combinations may also evolve. HIBISCUS permitted background standard-of-care treatment, reflecting the reality that sickle cell therapy increasingly involves layered management rather than a single universal drug.

The better the treatment landscape becomes, the less useful it may be to search for one winner.

What would make etavopivat commercially important rather than merely approvable?

Approval would answer only the first question.

Novo Nordisk will need to show physicians how a 27% reduction in annualised vaso-occlusive crises translates into meaningful patient outcomes across different baseline crisis frequencies, genotypes and background treatments. Full HIBISCUS safety data will be essential, particularly given the scrutiny created by Oxbryta’s withdrawal.

Pricing will then determine how aggressively payers position the medicine.

Etavopivat could face direct competition from mitapivat if Agios ultimately secures a sickle cell indication. Hydroxyurea will remain an inexpensive and familiar foundation of treatment for many patients, while genetic therapies provide a radically different option for eligible individuals with severe disease.

Commercial success could therefore depend less on claiming the largest efficacy number and more on occupying the broad space between established inexpensive therapy and highly intensive genetic intervention.

That space is enormous.

Sickle cell drug development has spent the past several years demonstrating what is scientifically possible. CRISPR editing can alter a patient’s own stem cells. Lentiviral gene addition can change haemoglobin biology. Pyruvate kinase activation can modify the metabolism of circulating red blood cells.

The next phase will test which of those technologies can actually reach patients at scale.

Etavopivat’s regulatory filings make that question newly concrete. Gene therapy may remain the most dramatic therapeutic option in sickle cell disease, but the treatment that reaches the greatest number of patients may ultimately look far less futuristic: a tablet taken once a day.

Leave a Reply

Your email address will not be published. Required fields are marked *